Zygomycoses - urgency in diagnosis

Authors

  • Dilip Abraham Post Graduate Resident, Dept. of Microbiology, Christian Medical College and Hospital, Ludhiana
  • Aroma Oberoi Professor & Head, Dept. of Microbiology, Christian Medical College and Hospital, Ludhiana
  • Eshani Dewan Assistant Professor, Dept. of Microbiology, Christian Medical College and Hospital, Ludhiana
  • Sangeetha Mohan Associate Professor, Dept. of Microbiology, Christian Medical College and Hospital, Ludhiana

DOI:

https://doi.org/10.14419/ijbas.v4i4.5004

Keywords:

Zygomycoses, Diabetic Patients, Diagnostic Urgency.

Abstract

Introduction: Zygomycoses is an angioinvasive infection most commonly seen in immunocompromised and diabetic patients. We undertook this study to determine the prevalence of Zygomycoses, in patients with a suspected Invasive Zygomycoses Infection in a tertiary centre and to identify the most common species isolated from culture.

Materials and Methods: A retrospective analysis was done from January 1, 2012 to December 8, 2014; the clinical data of the suspected patients and the positive cultures were collected.

Results and Discussion: A total of 50 samples of 27 patients with suspected Zygomycoses were sent during the 3 year period. In 25 of these patients, the samples sent were tissue biopsies from nasal cavity and 2 wound swabs from burns. Of these, 18 tissue biopsies of 13 patients and two wound swabs were detected positive for Zygomycetes. (2-Absidia corymbifera; 1-Rhizopus, 15-Mucor). Of the remaining 12 patients whose cultures were negative, 1–bacterial 1–bacterial sinusitis, 5-Invasive aspergillosis; 6-treated as Invasive fungal infections due to Zygomycetes as the imaging diagnostics and histopathological features favored that diagnosis. The majority of the patients (80%) were diabetic, and the two from the burn unit were under long-term treatment for chronic wound infections. Multiple diagnostic modalities must be used in view of the aggressive nature of the disease, but microbiological diagnosis remains the Gold Standard.

References

[1] M.M. Roden , T.E. Zaoutis, W.L. Buchanan et al. Epidemiology and Outcome of Zygomycosis: A Review of 929 Reported Cases. Clinical Infectious Diseases 41 (2005) 634–53. http://dx.doi.org/10.1086/432579.

[2] C.E. Gonzalez, M.G. Rinaldi and A.M. Sugar Zygomycosis. Infectious Disease Clinics of North America 16 (2002) 895–914. http://dx.doi.org/10.1016/S0891-5520(02)00037-5.

[3] R.N. Greenberg, L.J. Scott, H.H. Vaughn and J.A. Ribes Zygomycosis (mucormycosis): emerging clinical importance and new treatments. Current Opinion in Infectious Diseases 17 (2004) 517–25. http://dx.doi.org/10.1097/00001432-200412000-00003.

[4] C.A. Kauffman. Zygomycosis: reemergence of an old pathogen. Clinical Infectious Diseases 39 (2004) 588–90. http://dx.doi.org/10.1086/422729.

[5] R.M. Prabhu and R.Patel. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clinical Microbiology and Infection 10 (Suppl 1) (2004) 31–47. http://dx.doi.org/10.1111/j.1470-9465.2004.00843.x.

[6] A. Paultauf Mycosis mucorina. Virchows Archiv. A, Pathological anatomy and histology 102 (1885) 543. http://dx.doi.org/10.1007/BF01932420.

[7] J.A.Vazquez and J.D. Sobel. Fungal infections in diabetes. Infectious Disease Clinics of North America. 9 (1995) 97–116.

[8] W.A. Limongelli, M.S. Clark, R. Saglimbene, E.Baden, J.A.Washington and A.C.Williams. Successful treatment of mucocutaneous mucormycosis after dental extractio0s in a patient with uncontrolled diabetes. Journal of Oral and Maxillofacial Surgery 33 (1975) 705–712.

[9] K.A. Marr, R.A. Carter, F. Crippa, A. Wald and L. Corey. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases 34 (2002) 909–917. http://dx.doi.org/10.1086/339202.

[10] D.P. Kontoyiannis, M.S. Lionakis, R.E. Lewis, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. The Journal of Infectious Diseases 191 (2005) 1350–1360. http://dx.doi.org/10.1086/428780.

[11] J.R. Boelaert, A.Z. Fenves and J.W. Coburn. Deferoxamine therapy and mucormycosis in dialysis patients: report of an international registry. American Journal of Kidney Diseases 18 (1991) 660–667. http://dx.doi.org/10.1016/S0272-6386(12)80606-8.

[12] A. Skiada, A.H. Groll, L. Pagano, R.H. Zimmerli, O. Lortholary and G. Petrikkos. Diagnosis and treatment of zygomycosis: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3) Haematologica 98(4) (2013) 492-504. http://dx.doi.org/10.3324/haematol.2012.065110.

[13] D. Neofytos, D. Horn, E. Anaissie, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clinical Infectious Diseases 48 (2009) 265-273. http://dx.doi.org/10.1086/595846.

[14] M.J. Ruping, W.J. Heinz, A.J. Kindo, et al. Forty-one recent cases of invasive zygomycosis from a global clinical registry. Journal of Antimicrobial Chemotherapy 65 (2010) 296-302. http://dx.doi.org/10.1093/jac/dkp430.

[15] A. Chakrabarti, S.S. Chatterjee, A. Das, et al. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgraduate Medical Journal 85 (2009) 573-581. http://dx.doi.org/10.1136/pgmj.2008.076463.

[16] D.P. Kontoyiannis, V.C.Wessel, G.P. Bodey and K.V. Rolston. Zygomycosis in the 1990s in a tertiary-care cancer center. Clinical Infectious Diseases 30 (2000) 851–856. http://dx.doi.org/10.1086/313803.

[17] J.A. Ribes, C.L. Vanover-Sams and D.J. Baker. Zygomycetes in human disease. Clinical Microbiology Reviews 13 (2000) 236–301. http://dx.doi.org/10.1128/CMR.13.2.236-301.2000.

Downloads

Published

2015-10-23

Issue

Section

Articles